Treatment of faecal incontinence with autologous expanded mesenchymal stem cells: results of a pilot study

Aim Management of faecal incontinence (FI) remains challenging because no definitive optimal treatment for this condition has yet been determined. Regenerative medicine could be an attractive therapeutic alternative for treating FI. Here, we aimed to determine the safety and feasibility of autologou...

Full description

Saved in:
Bibliographic Details
Published in:Colorectal disease Vol. 23; no. 3; pp. 698 - 709
Main Authors: Portilla, Fernando, Guerrero, José Luis, Maestre, Maria Victoria, Leyva, Laura, Mera, Santiago, García‐Olmo, Damián, Rodríguez, Antonio, Mata, Rosario, Lora, Fabiola
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-03-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Management of faecal incontinence (FI) remains challenging because no definitive optimal treatment for this condition has yet been determined. Regenerative medicine could be an attractive therapeutic alternative for treating FI. Here, we aimed to determine the safety and feasibility of autologous expanded mesenchymal stem cells derived from adipose tissue (AdMSCs) in the treatment of patients diagnosed with structural FI. Method This was a randomized, multicentre, triple‐blinded, placebo‐controlled pilot study conducted at four sites in Spain with 16 adults with FI and a sphincter defect. Autologous AdMSCs were obtained from patients from surgically excised adipose tissue. These patients were intralesionally infused with a single dose of 4 × 107 AdMSCs or a placebo while under anaesthesia. We assessed the safety and feasibility of the treatment as the cumulative incidence of adverse events and the treatment efficacy using the Cleveland Clinic Faecal Incontinence Score, Faecal Incontinence Quality of Life score and Starck criteria to classify sphincter defects and anorectal physiology outcomes. Results Adipose tissue extraction, cell isolation and intralesional infusion procedures were successful in all the patients. There was only one adverse event connected to adipose tissue extraction (a haematoma), and none was associated with the injection procedure. There were no significant differences in any of the assessed clinical, manometric or ultrasonographic parameters. Conclusion This study indicates that this infusion procedure in the anal sphincter is feasible and safe. However, it failed to demonstrate efficacy to treat patients with structural FI.
Bibliography:Funding information
This project received partial funding from the Andalusian Ministry of Health (grant number PI‐0424‐2013).
Data from this paper were presented as a poster at the ISCT Europe 2018, Regional Meeting in Florence, Italy, held between 12 and 14 September 2018.
Clinical trial registration: ClinicalTrials.gov identifier: NCT02292628
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:1462-8910
1463-1318
DOI:10.1111/codi.15382